LILRB2 and non-small cell lung carcinoma: Since immunosuppressive TME, one of the major causes for ICI resistance in EGFR mutant patients, could be partially reversed by ILT4 inhibition, we speculated that ILT4 blockade might be effective to overcome the primary hypo-responsiveness of ICIs in this NSCLC subpopulation.